Lilianny Querino Rocha de Oliveira

Ms. Lilianny Querino Rocha de Oliveira


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Everton Freitas de MoraisEverton Freitas de Morais
Everton Freitas de Morais
Lilianny Querino Rocha de OliveiraLilianny Querino Rocha de Oliveira
Lilianny Querino Rocha de Oliveira
HMHannah Gil de Farias Morais
Hannah Gil de Farias Morais
MMMaurília Raquel de Souto Medeiros
Maurília Raquel de Souto Medeiros
RFRoseana De Almeida Freitas
Roseana De Almeida Freitas
Ricardo D. ColettaRicardo D. Coletta
Ricardo D. Coletta
Given the heterogeneity of different malignant processes, planning cancer treatment is challenging. According to recent studies, natural products are likely to be effective in cancer prevention and treatment. Among bioactive flavonoids found in fruits and vegetables, kaempferol (KMP) is known for its anti-inflammatory, antioxidant, and anticancer properties. This systematic review aims to highlight the potential therapeutic effects of KMP on different types of solid malignant tumors. This review was conducted following the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines. Searches were performed in EMBASE, Medline/PubMed, Cochrane Collaboration Library, Science Direct, Scopus, and Google Scholar. After the application of study criteria, 64 studies were included. In vitro experiments demonstrated that KMP exerts antitumor effects by controlling tumor cell cycle progression, proliferation, apoptosis, migration, and invasion, as well as by inhibiting angiogenesis. KMP was also able to inhibit important markers that regulate epithelial–mesenchymal transition and enhanced the sensitivity of cancer cells to traditional drugs used in chemotherapy, including cisplatin and 5-fluorouracil. This flavonoid is a promising therapeutic compound and its combination with current anticancer agents, including targeted drugs, may potentially produce more effective and predictable results.

6 February 2024 in Biology
Verified
Journal Article
Open access
PDF file
LRLeonardo Siquara da Rocha
Leonardo Siquara da Rocha
Everton Freitas de MoraisEverton Freitas de Morais
Everton Freitas de Morais
Lilianny Querino Rocha de OliveiraLilianny Querino Rocha de Oliveira
Lilianny Querino Rocha de Oliveira
ABAndressa Vollono Barbosa
Andressa Vollono Barbosa
DLDaniel Lambert
Daniel Lambert
Ricardo D. ColettaRicardo D. Coletta
Ricardo D. Coletta
Oral squamous cell carcinoma (OSCC) is the most common and lethal type of head and neck cancer in the world. Variable response and acquisition of resistance to traditional therapies show that it is essential to develop novel strategies that can provide better outcomes for the patient. Understanding of cellular and molecular mechanisms of cell death control has increased rapidly in recent years. Activation of cell death pathways, such as the emerging forms of non-apoptotic programmed cell death, including ferroptosis, pyroptosis, necroptosis, NETosis, parthanatos, mitoptosis and paraptosis, may represent clinically relevant novel therapeutic opportunities. This systematic review summarizes the recently described forms of cell death in OSCC, highlighting their potential for informing diagnosis, prognosis and treatment. Original studies that explored any of the selected cell deaths in OSCC were included. Electronic search, study selection, data collection and risk of bias assessment tools were realized. The literature search was carried out in four databases, and the extracted data from 79 articles were categorized and grouped by type of cell death. Ferroptosis, pyroptosis, and necroptosis represented the main forms of cell death in the selected studies, with links to cancer immunity and inflammatory responses, progression and prognosis of OSCC. Harnessing the potential of these pathways may be useful in patient-specific prognosis and individualized therapy. We provide perspectives on how these different cell death types can be integrated to develop decision tools for diagnosis, prognosis, and treatment of OSCC.

24 August 2025 in Cells
Verified
Journal Article
Open access
PDF file
Everton Freitas de MoraisEverton Freitas de Morais
Everton Freitas de Morais
Lilianny Querino Rocha de OliveiraLilianny Querino Rocha de Oliveira
Lilianny Querino Rocha de Oliveira
CMCintia Eliza Marques
Cintia Eliza Marques
FTFábio Haach Téo
Fábio Haach Téo
GRGisele Vieira Rocha
Gisele Vieira Rocha
Ricardo D. ColettaRicardo D. Coletta
Ricardo D. Coletta
Cisplatin resistance remains a major therapeutic challenge in oral squamous cell carcinoma (OSCC), leading to treatment failure and poor outcomes. This study aimed to generate and characterize cisplatin-resistant OSCC models to elucidate resistance mechanisms. Two resistant OSCC cell lines (SCC-9R and HSC-3R) were developed through gradual dose escalation. Parental and resistant cells were analyzed via RNA-seq and gene set enrichment analysis, and validated through RT-qPCR, Western blot, immunofluorescence, and gelatin zymography. Functional assays, including 2D and 3D migration and invasion models, assessed phenotypic changes. A multi-omics analysis revealed molecular alterations in resistant cells, including 305 differentially expressed genes (DEGs) in HSC-3R (187 upregulated) and 782 in SCC-9R (298 upregulated) versus parental lines, with enrichment for extracellular matrix organization (p < 0.001) and consistent epithelial–mesenchymal transition (EMT) activation (p < 0.001), demonstrated by the upregulation of ZEB1, ZEB2, Vimentin, and TWIST1, and E-cadherin suppression. Functional validation confirmed an aggressive phenotype, including increased migration (p < 0.05), invasion (p < 0.01), and elevated MMP-2 (p < 0.01) and MMP-9 (p < 0.001) activity. Findings were verified in 3D spheroid models. Overall, cisplatin resistance in OSCC involves EMT, inflammatory signaling, and metabolic adaptation. The consistency of these features across both models supports the robustness of this in vitro system and reveals targets for therapeutic intervention.

6 January 2025 in Oral Diseases
Verified
Journal Article
Closed access
SASara Garcia Azevedo
Sara Garcia Azevedo
Lilianny Querino Rocha de OliveiraLilianny Querino Rocha de Oliveira
Lilianny Querino Rocha de Oliveira
HMHercilio Martelli-Junior
Hercilio Martelli-Junior
Ricardo D. ColettaRicardo D. Coletta
Ricardo D. Coletta
RMRenato Assis Machado
Renato Assis Machado

1 January 2024 in Journal of Applied Oral Science
Verified
Journal Article
Open access
PDF file
LLLorraynne dos Santos Lara
Lorraynne dos Santos Lara
Ricardo D. ColettaRicardo D. Coletta
Ricardo D. Coletta
RMRenato Assis Machado
Renato Assis Machado
Lilianny Querino Rocha de OliveiraLilianny Querino Rocha de Oliveira
Lilianny Querino Rocha de Oliveira
HMHercilio Martelli-Junior
Hercilio Martelli-Junior
LVLuiz Evaristo Ricci Volpato
Luiz Evaristo Ricci Volpato
Associations between the WNT5A rs566926 variant and non-syndromic orofacial cleft (NSOC) have been reported in different populations.

5 January 2026 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Everton Freitas de MoraisEverton Freitas de Morais
Everton Freitas de Morais
Lilianny Querino Rocha de OliveiraLilianny Querino Rocha de Oliveira
Lilianny Querino Rocha de Oliveira
CMCintia Eliza Marques
Cintia Eliza Marques
HMHannah Gil de Farias Morais
Hannah Gil de Farias Morais
DMDéborah Gondim Lambert Moreira
Déborah Gondim Lambert Moreira
Ricardo D. ColettaRicardo D. Coletta
Ricardo D. Coletta
Oral squamous cell carcinoma (OSCC) remains a highly prevalent and aggressive malignancy with limited improvements in survival rates. One of the major obstacles to successful treatment is the development of chemoresistance, which contributes to recurrence, metastasis, and treatment failure. This narrative review aims to integrate current evidence on the molecular and cellular mechanisms that drive chemoresistance in OSCC and to delineate how these processes converge under therapeutic pressure. A structured search was performed to identify relevant studies addressing chemoresistance in OSCC, focusing on preclinical and translational evidence. Multiple interconnected mechanisms have been implicated in driving resistance in OSCC, including epigenetic alterations, deregulated signaling pathways, cancer stem cell plasticity, epithelial–mesenchymal transition (EMT), interactions with the tumor microenvironment (TME), drug efflux mediated by ATP-binding cassette (ABC) transporters, and enhanced DNA damage response. In combination, these mechanisms support tumor persistence and limit effective antitumor immunity. Emerging strategies such as epigenetic modulators, signaling pathway inhibitors, immunomodulation, and nanomedicine-based delivery systems have shown promising results in preclinical models. By highlighting convergent resistance networks, this integrative perspective supports the rational design of combination therapies and biomarker-guided strategies aimed at overcoming chemoresistance in OSCC.